Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 3, 2013, Pages 608-617

  Binder, Nikolaus B ^a   Puchner, Antonia ^a   Niederreiter, Birgit ^a   Hayer, Silvia ^a   Leiss, Harald ^a   Blüml, Stephan ^a   Kreindl, Roman ^a   Smolen, Josef S ^a   Redlich, Kurt ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; BONE DESTRUCTION; BONE EROSION; BONE MARROW; CELL MEMBRANE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LOW DRUG DOSE; MONOCYTE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRECURSOR; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; SYNOVIOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BONE AND BONES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; OSTEOCLASTS; RANK LIGAND; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; STEM CELLS; SYNOVIAL MEMBRANE; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874422827     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37797     Document Type: Article

References (38)

1. Feldmann M, Maini SR,. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008; 223: 7-19.
2. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
3. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest 2002; 110: 1419-27.
4. Walsh NC, Gravallese EM,. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010; 233: 301-12.
5. Teitelbaum SL,. Bone resorption by osteoclasts. Science 2000; 289: 1504-8.
6. Takahashi N, Udagawa N, Suda T,. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999; 256: 449-55.
7. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-602.
8. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL,. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-8.
9. Abu-Amer Y, Ross FP, Edwards J, Teitelbaum SL,. Lipopolysaccharide- stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997; 100: 1557-65.
10. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191: 275-86.
11. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005; 7: R796-806.
12. Van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB,. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31: 519-25.
13. Van Leeuwen MA, van der Heijde DM, van Rijswijk MH, Houtman PM, van Riel PL, van de Putte LB, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994; 21: 425-9.
14. Klarenbeek NB, Guler-Yuksel M, van der Heijde DM, Hulsmans HM, Kerstens PJ, Molenaar TH, et al. Clinical synovitis in a particular joint is associated with progression of erosions and joint space narrowing in that same joint, but not in patients initially treated with infliximab. Ann Rheum Dis 2010; 69: 2107-13.
15. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy study. Arthritis Rheum 2005; 52: 1020-30.
16. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S,. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the Trial of Etanercept and Methotrexate with Radiographic and Patient Outcomes. Arthritis Rheum 2006; 54: 3119-25.
17. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH,. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009; 36: 1429-41.
18. Bluml S, Binder NB, Niederreiter B, Polzer K, Hayer S, Tauber S, et al. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum 2010; 62: 1608-19.
19. Eferl R, Hasselblatt P, Rath M, Popper H, Zenz R, Komnenovic V, et al. Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1. Proc Natl Acad Sci U S A 2008; 105: 10525-30.
20. Leonard JP, Lacasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597-607.
21. high osteoclast precursors in tumor necrosis factor α-transgenic mice. Arthritis Rheum 2004; 50: 265-76.
22. Hayer S, Steiner G, Gortz B, Reiter E, Tohidast-Akrad M, Amling M, et al. CD44 is a determinant of inflammatory bone loss. J Exp Med 2005; 201: 903-14.
23. hi osteoclast precursors but is essential for mature osteoclast formation in TNFα-mediated inflammatory arthritis. J Bone Miner Res 2004; 19: 207-13.
24. Yao Z, Li P, Zhang Q, Schwarz EM, Keng P, Arbini A, et al. Tumor necrosis factor-α increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J Biol Chem 2006; 281: 11846-55.
25. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
26. Feldmann M, Brennan FM, Maini RN,. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
27. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS,. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-23.
28. Crotti TN, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, et al. Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. Ann Rheum Dis 2002; 61: 1047-54.
29. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor α treatment. Arthritis Rheum 2002; 46: 1744-53.
30. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR,. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943-51.
31. Chiu YG, Shao T, Feng C, Mensah KA, Thullen M, Schwarz EM, et al. CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther; 12: R14.
32. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O,. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008; 10: 208.
33. Smolen JS, Avila JC, Aletaha D,. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis 2012; 71: 687-93.
34. Walsh NC, Crotti TN, Goldring SR, Gravallese EM,. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005; 208: 228-51.
35. Axmann R, Bohm C, Kronke G, Zwerina J, Smolen J, Schett G,. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 2009; 60: 2747-56.
36. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007; 104: 11742-7.
37. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50: 277-90.
38. Saxne T, Heinegard D, Wollheim FA, Pettersson H,. Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis. Lancet 1985; 2: 127-8.